You should read Dario Amodei’s latest essay

If you’re staying on top of AI news, you probably don’t need me to tell you to read Anthropic CEO Dario Amodei’s latest essay. That said … you should read Dario Amodei’s latest essay. It’s the most detailed look at the company’s public policy attitudes to date, and particularly interesting to the AGF team because of how much Amodei focuses on clinical trials. As he writes, AI seems likely to "greatly increase the rate at which new drug candidates enter the regulatory pipeline"; but that pipeline is so long and slow that it will be hard for customers to enjoy those drug candidates in a timely way. That implies that we need major reforms to the way the Food and Drug Administration and European Medicines Agency evaluate drug candidates, to make sure new, promising therapies aren't languishing for years before approval.